EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Brimonidine-Loaded Ethosomes for Glaucoma: Investigation of Intraocular Pressure-Lowering Potential In Vivo

Samet Özdemir iD, Ali Asram Sağıroğlu iD, Eslim Şen iD, Büşra Gelmez Yıldız iD, Laman Karimli, Meltem Ezgi Durgun Kılıç iD, Ali Riza Cenk Celebi, Yıldız Özsoy iD

Pharmaceutics · 06.02.2026 · 18 (2) · 210

DOI: 10.3390/pharmaceutics18020210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 06.02.2026. Verfasst von Samet Özdemir und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul 34445, Türkiye. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Acibadem University Scientific Research Projects Coordination Unit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Brimonidine tartrate (BRT), a selective α2-adrenergic receptor agonist, is commonly used in the treatment of glaucoma. However, conventional eye drop formulations suffer from poor ocular bioavailability and rapid elimination. This study aimed to develop and evaluate BRT-loaded ethosomes as a nanocarrier-based alternative to enhance intraocular delivery and therapeutic efficacy.

Methods

Ethosomes were prepared using the thin-film hydration method and optimized via central composite design. The optimized formulation was subjected to physicochemical characterization, in vitro release testing, and ocular irritation assessment using the Hen egg test—chorioallantoic membrane (HET-CAM) model. Additionally, the intraocular pressure (IOP)-lowering efficacy of the formulation was evaluated in a rat glaucoma model.

Results

The optimized ethosomal formulation exhibited favorable physicochemical properties, including a mean particle size of 122.6 ± 0.7 nm, zeta potential of −1.8 ± 0.9 mV, and encapsulation efficiency of 87.33 ± 0.04%. In vitro release data followed Higuchi kinetics. HET-CAM analysis indicated non-irritancy. In vivo, the ethosomal BRT formulation achieved comparable IOP-lowering effects to the marketed eye drops at one-third of the dose.

Conclusions

The developed BRT-loaded ethosomal system demonstrated promising physicochemical stability, sustained release, and therapeutic potential. These findings suggest that ethosomes may offer a safe and effective strategy for enhancing the ocular delivery of BRT in glaucoma therapy.

Schlagwörter

Stichwörter der Autor:innen

HET-CAMbrimonidine tartrateethosomesglaucomaintraocular pressureophthalmic drug delivery

Autor:innen und Institutionen

  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul 34445, Türkiye.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University-Cerrahpasa, Istanbul 34500, Türkiye.
  • Department of Ophthalmology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul 34636, Türkiye.
  • Department of Ophthalmology, Faculty of Medicine, Istanbul Health and Technology University, Istanbul 34445, Türkiye.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Türkiye.

ORCID-Profile: Samet Özdemir, Ali Asram Sağıroğlu, Eslim Şen, Büşra Gelmez Yıldız, Meltem Ezgi Durgun Kılıç, Yıldız Özsoy

Förderung

  • Acibadem University Scientific Research Projects Coordination Unit

Zitieren

APA

Özdemir, S., Sağıroğlu, A. A., Şen, E., Gelmez Yıldız, B., Karimli, L., Durgun Kılıç, M. E., Celebi, A. R. C., & Özsoy, Y. (2026). Development of Brimonidine-Loaded Ethosomes for Glaucoma: Investigation of Intraocular Pressure-Lowering Potential In Vivo. Pharmaceutics, 18(2), 210. https://doi.org/10.3390/pharmaceutics18020210

Vancouver

Özdemir S, Sağıroğlu AA, Şen E, Gelmez Yıldız B, Karimli L, Durgun Kılıç ME, et al. Development of Brimonidine-Loaded Ethosomes for Glaucoma: Investigation of Intraocular Pressure-Lowering Potential In Vivo. Pharmaceutics. 2026;18(2):210. doi:10.3390/pharmaceutics18020210

BibTeX
@article{zdemir2026,
  author = {Özdemir, Samet and Sağıroğlu, Ali Asram and Şen, Eslim and Gelmez Yıldız, Büşra and Karimli, Laman and Durgun Kılıç, Meltem Ezgi and Celebi, Ali Riza Cenk and Özsoy, Yıldız},
  title = {Development of Brimonidine-Loaded Ethosomes for Glaucoma: Investigation of Intraocular Pressure-Lowering Potential In Vivo},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {210},
  doi = {10.3390/pharmaceutics18020210}
}
Kostenlos starten →